<DOC>
	<DOCNO>NCT00434668</DOCNO>
	<brief_summary>The aim study evaluate tolerability ( term drug delivery toxicity ) four cycle adjuvant docetaxel plus cisplatin patient completely resect stage IB-II Non-Small Cell Lung Cancer . To avoid selection bias , eligible patient randomise receive cisplatin/docetaxel cisplatin/vinorelbine .</brief_summary>
	<brief_title>Evaluation Tolerability Adjuvant Cisplatin/Docetaxel Completely Resected Stage IB/II Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>completely resected pathological stage IB II NSCLC adequate haematological , renal liver function condition previous chemo radiotherapy NSCLC bronchoalveolar cell subtype second active primary malignancy serious concomitant medical disease difficulty adequate followup</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>Non-Small Cell Lung Cancer</keyword>
	<keyword>NSCLC</keyword>
	<keyword>Adjuvant chemotherapy completely resect NSCLC</keyword>
</DOC>